Celsion Corp (CLSN):医療機器:M&Aディール及び事業提携情報

◆英語タイトル:Celsion Corp (CLSN) - Medical Equipment - Deals and Alliances Profile
◆商品コード:DATA904C7038
◆発行会社(調査会社):GlobalData
◆発行日:2018年10月
◆ページ数:53
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:医療機器
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Celsion Corp (Celsion) is an oncology company that strives to develop a portfolio of new cancer treatments, including directed chemotherapies, RNA or DNA based therapies and immunotherapies. The company’s three platform technologies including Lysolipid Thermally Sensitive Liposomes (LTSL), TheraPlas and TheraSilence provide the foundation for a wide range of treatments for common and difficult-to-treat forms of cancers. Its lead product candidate ThermoDox is a proprietary form of doxorubicin based LTSL technology in a Phase III clinical trial for the treatment of non-resectable hepatocellular carcinoma (HCC) and a Phase II clinical trial for recurrent chest wall (RCW) breast cancer. It is also developing a comprehensive pipeline of targeted therapeutic agents. Celsion is headquartered in Lawrenceville, New Jersey, the US.

Celsion Corp (CLSN) – Medical Equipment – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Medical eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Celsion Corp, Medical Equipment, Deals By Year, 2012 to YTD 2018 5
Celsion Corp, Medical Equipment Deals By Type, 2012 to YTD 2018 6
Celsion Corp, Medical Equipment, Deals By Region, 2012 to YTD 2018 7
Celsion Corp, Medical Equipment, Deals By Market, 2012 to YTD 2018 8
Celsion Corp, Medical Equipment, Deals Summary, 2012 to YTD 2018 9
Celsion Corp, Medical Equipment, Deal Details 10
Equity Offering 10
Celsion Plans to Raise up to USD75.5 Million in Public Offering of Securities 10
Celsion to Raise USD15 Million in Public Offering of Shares 11
Celsion to Raise up to USD10 Million in Public Offering of Shares 12
Celsion Plans to Raise up to USD7.4 Million in Private Placement of Shares up on Exercise of Warrants 13
Celsion Raises USD6.6 Million in Public Offering of Shares 14
Celsion Plans to Raise Funds through Private Placement of Shares up on Exercise of Warrants 15
Celsion to Raise up to USD2.4 Million in Public Offering of Shares 16
Celsion Raises USD5 Million in Public Offering of Shares and Warrants 17
Celsion Raises USD1.8 Million in Private Placement of Shares and Warrants 18
Celsion Raises USD6 Million in Private Placement of Shares 19
Celsion Raises USD8 Million in Private Placement of Shares 20
Celsion Raises USD15 Million in Private Placement Of Common Stock 21
Celsion Corp – Key Competitors 22
Celsion Corp – Key Employees 23
Celsion Corp – Locations And Subsidiaries 24
Head Office 24
Recent Developments 25
Financial Announcements 25
Aug 14, 2018: Celsion announces second quarter 2018 financial results 25
Jul 11, 2018: Horizon Technology Finance provides investment portfolio update 28
May 11, 2018: Celsion Reports First Quarter 2018 Financial Results and Provides Business Update 30
Mar 27, 2018: Celsion Announces Fourth Quarter And Full-Year 2017 Financial Results 33
Nov 14, 2017: Celsion Reports Third Quarter 2017 Financial Results and Provides Business Update 36
Aug 15, 2017: Celsion Reports Second Quarter 2017 Financial Results and Provides Business Update 39
May 12, 2017: Celsion Reports First Quarter 2017 Financial Results and Provides Business Update 42
Mar 16, 2017: Celsion Reports Year End 2016 Financial Results and Provides Business Update 44
Corporate Communications 46
Jul 11, 2018: Horizon Technology Finance provides investment portfolio update 46
Legal and Regulatory 48
Jun 25, 2018: Celsion to join Russell Microcap Index 48
Jun 14, 2018: Celsion regains compliance with NASDAQ listing requirements 49
Aug 04, 2017: Celsion to Delist from the Tel Aviv Stock Exchange 50
Other Significant Developments 51
Jul 11, 2018: Horizon Technology Finance provides investment portfolio update 51
Appendix 53
Methodology 53
About GlobalData 53
Contact Us 53
Disclaimer 53

List of Tables
Celsion Corp, Medical Equipment, Key Facts, 2017 2
Celsion Corp, Medical Equipment, Deals Summary, 2012 to YTD 2018 2
Celsion Corp, Medical Equipment, Deals By Year, 2012 to YTD 2018 5
Celsion Corp, Medical Equipment Deals By Type, 2012 to YTD 2018 6
Celsion Corp, Medical Equipment, Deals By Region, 2012 to YTD 2018 7
Celsion Corp, Deals By Market, 2012 to YTD 2018 8
Celsion Corp, Medical Equipment, Deals Summary, 2012 to YTD 2018 9
Celsion Plans to Raise up to USD75.5 Million in Public Offering of Securities 10
Celsion to Raise USD15 Million in Public Offering of Shares 11
Celsion to Raise up to USD10 Million in Public Offering of Shares 12
Celsion Plans to Raise up to USD7.4 Million in Private Placement of Shares up on Exercise of Warrants 13
Celsion Raises USD6.6 Million in Public Offering of Shares 14
Celsion Plans to Raise Funds through Private Placement of Shares up on Exercise of Warrants 15
Celsion to Raise up to USD2.4 Million in Public Offering of Shares 16
Celsion Raises USD5 Million in Public Offering of Shares and Warrants 17
Celsion Raises USD1.8 Million in Private Placement of Shares and Warrants 18
Celsion Raises USD6 Million in Private Placement of Shares 19
Celsion Raises USD8 Million in Private Placement of Shares 20
Celsion Raises USD15 Million in Private Placement Of Common Stock 21
Celsion Corp, Key Competitors 22
Celsion Corp, Key Employees 23

List of Figures
Celsion Corp, Medical Equipment, Deals by Type, 2012 to YTD 2018 2
Celsion Corp, Medical Equipment, Deals By Year, 2012 to YTD 2018 2
Celsion Corp, Medical Equipment, Deals By Region, 2012 to YTD 2018 2
Celsion Corp, Medical Equipment, Deals By Market, 2012 to YTD 2018 2
Celsion Corp, Medical Equipment, Deals By Year, 2012 to YTD 2018 5
Celsion Corp, Medical Equipment, Deals by Type, 2012 to YTD 2018 6
Celsion Corp, Medical Equipment, Deals By Region, 2012 to YTD 2018 7
Celsion Corp, Medical Equipment, Deals by Market, 2012 to YTD 2018 8

★海外企業調査レポート[Celsion Corp (CLSN):医療機器:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Teollisuuden Voima Oyj:企業の戦略的SWOT分析
    Teollisuuden Voima Oyj - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and …
  • SEEK Limited:企業の戦略・SWOT・財務情報
    SEEK Limited - Strategy, SWOT and Corporate Finance Report Summary SEEK Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate a …
  • Red Hat Inc:企業の戦略的SWOT分析
    Red Hat Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. …
  • Cue Health Inc:企業の製品パイプライン分析2018
    Summary Cue Health Inc (Cue Health) is a healthcare technology company that strives to design, develop, manufacture and commercialize medical diagnostic products for use in home and clinical settings. The company’s lead product, Cue Health Monitoring System, is a connected diagnostic platform that h …
  • Dixons Carphone plc:企業の戦略・SWOT・財務情報
    Dixons Carphone plc - Strategy, SWOT and Corporate Finance Report Summary Dixons Carphone plc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings a …
  • Piramal Enterprises Ltd (PEL):医療機器:M&Aディール及び事業提携情報
    Summary Piramal Enterprises Ltd (PEL), is a provider of medicines and healthcare finance services. The company offers products such as Critical Care, Consumer Care, BST-CarGel, Phyto Medicines, Anaesthesias, Orthopedic medicines, Halothane, Isoflurane , Sevoflurane and other OTC related medicines. I …
  • Max Delbruck Center for Molecular Medicine:製薬・医療:M&Aディール及び事業提携情報
    Summary Max Delbruck Center for Molecular Medicine (MDC) is a biomedical research center that offers translating discoveries from molecular research into applications. The company’s research area services offer for cancer research, cardiovascular and metabolic disease, diseases of the nervous system …
  • Rockwool International AS:戦略・SWOT・企業財務分析
    Rockwool International AS - Strategy, SWOT and Corporate Finance Report Summary Rockwool International AS - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service …
  • New England Biolabs Inc-製薬・医療分野:企業M&A・提携分析
    Summary New England Biolabs Inc (NEB) is a life science company that develops recombinant and native enzymes for genomic research. The company offers products such as competent cells, DNA plasmids, protein tools, buffers and strains, and others. It has applications in cloning and synthetic biology, …
  • Trident Limited:戦略・SWOT・企業財務分析
    Trident Limited - Strategy, SWOT and Corporate Finance Report Summary Trident Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpo …
  • Suzhou Xinrong Best Medical Instrument Co Ltd-医療機器分野:企業M&A・提携分析
    Summary Suzhou Xinrong Best Medical Instrument Co Ltd (Suzhou Xinrong) is a medical device company that manufactures orthopedic medical instruments. The company prvides products such as medullary cavity plug, acetabular screws, metal ball head, stem and titanium plate anterior thoracolumbar fixed eq …
  • Therapix Biosciences Ltd (TRPX):製薬・医療:M&Aディール及び事業提携情報
    Summary Therapix Biosciences Ltd (Therapix), formerly Nasvax Ltd is a clinical stage biopharmaceutical company that focuses on the development of cannabinoid based pharmaceuticals for the treatment of central nervous system disorders. Therapix’s major product candidates include THX-110, for the trea …
  • TEGNA Inc (TGNA):企業の財務・戦略的SWOT分析
    TEGNA Inc (TGNA) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the …
  • DePuy Synthes Inc:企業の製品パイプライン分析2018
    Summary DePuy Synthes Inc (DePuy Synthes), a subsidiary of Johnson & Johnson, is a medical device company that provides products for orthopedic and neurological procedures. DePuy Synthes operates through eight divisions: joint reconstruction, sports medicine, neurological, spine, trauma, cranio-maxi …
  • United Networks Ltd (UNL):企業の財務・戦略的SWOT分析
    United Networks Ltd (UNL) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses …
  • Martin Midstream Partners L.P.:企業のM&A・事業提携・投資動向
    Martin Midstream Partners L.P. - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Martin Midstream Partners L.P. Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers a …
  • Industrija nafte d.d. (INA-R-A):石油・ガス:M&Aディール及び事業提携情報
    Summary Industrija nafte dd (INA) is an integrated energy company, which operates across the energy value chain from exploration and production to refining and marketing to retail. It has interests in offshore and onshore assets in Croatia, Egypt, and Angola. The company manages refineries in Rijeka …
  • Frontier Communications Corporation:企業の戦略・SWOT・財務情報
    Frontier Communications Corporation - Strategy, SWOT and Corporate Finance Report Summary Frontier Communications Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, …
  • IXICO Plc (IXI):企業の財務・戦略的SWOT分析
    Summary IXICO Plc (IXICO), formerly Phytopharm plc is a provider of clinical trial services and technology for the evaluation of imaging endpoints and assessing the safety and efficacy of drugs. The company offers products such as Assessa and trial tracker. Assessa provides web-based platform to tra …
  • LG Uplus Corp:企業の戦略・SWOT・財務情報
    LG Uplus Corp - Strategy, SWOT and Corporate Finance Report Summary LG Uplus Corp - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆